https://www.live-feeds.com/feed/new-mrna-vaccine-could-reduce-the-recurrence-and-spread-of-skin-cancerContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/new-mrna-vaccine-could-reduce-the-recurrence-and-spread-of-skin-cancerhttps://www.live-feeds.com/feed/new-mrna-vaccine-could-reduce-the-recurrence-and-spread-of-skin-cancer#u47319Mon, 24 Aug 2026 08:15:41 +0000A personalized mRNA vaccine combined with the immunotherapy drug pembrolizumab significantly reduced the risk of melanoma recurrence and spread in high-risk patients. Moderna and Merck announced the results this week, confirming the treatment successfully cleared phase 3 clinical trials. This neoantigen treatment instructs cells to produce proteins tailored to individual tumors to prevent the cancer from returning. The trial results move the vaccine to the final step before it can seek approval from the FDA.Why it mattersPrevious reports established the promise of mRNA vaccines in oncology. Th https://www.live-feeds.com/feed/new-mrna-vaccine-could-reduce-the-recurrence-and-spread-of-skin-cancerhttps://www.live-feeds.com/feed/new-mrna-vaccine-could-reduce-the-recurrence-and-spread-of-skin-cancer#u45861Fri, 21 Aug 2026 10:25:24 +0000Moderna's experimental mRNA vaccine, in combination with Merck's cancer drug Keytruda, has shown promise in reducing the recurrence and spread of skin cancer, according to recent trial results. The vaccine, which uses a piece of genetic material called messenger RNA to instruct cells to produce a specific protein, has been found to be effective in reducing the risk of skin cancer recurrence. The results have sparked optimism about the potential for mRNA vaccines to be used in the treatment and prevention of cancer.Why it mattersThe development of mRNA vaccines has been a significant